Northwest Biotherapeutics Inc (NWBO): Operating Cash Flow
-$44.76M
Year ended 2025-12-31
-$48.34M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$44.76M | n/m | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | -$57.02M | n/m | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | -$53.64M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$52.77M | n/m | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | -$38.30M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$32.09M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$31.86M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$34.59M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$36.49M | n/m | 2019-04-02, From 2017-01-01 |
| 2016-12-31 | -$55.65M | n/m | 2018-04-17, From 2016-01-01 |
| 2015-12-31 | -$78.61M | n/m | 2016-03-16, From 2015-01-01 |
| 2014-12-31 | -$54.58M | n/m | 2016-03-16, From 2014-01-01 |
| 2013-12-31 | -$37.80M | n/m | 2016-03-16, From 2013-01-01 |
| 2012-12-31 | -$22.75M | n/m | 2014-04-01, From 2012-01-01 |
| 2011-12-31 | -$14.71M | n/m | 2013-04-08, From 2011-01-01 |
| 2010-12-31 | -$6.38M | n/a | 2012-04-13, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$44.76M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$789.1K | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$1.83M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$14.11M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$4.79M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$66.44M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$18.64M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$12.35M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$18.71M | n/m |
Compare NWBO, CPMD, ATXI, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗